Yili Chuanning BiotechnologyLtd Résultats passés
Passé contrôle des critères 5/6
Yili Chuanning BiotechnologyLtd has been growing earnings at an average annual rate of 47.4%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 12.9% per year. Yili Chuanning BiotechnologyLtd's return on equity is 18.1%, and it has net margins of 24.2%.
Informations clés
47.4%
Taux de croissance des bénéfices
53.0%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 11.3% |
| Taux de croissance des recettes | 12.9% |
| Rendement des fonds propres | 18.1% |
| Marge nette | 24.2% |
| Dernière mise à jour des bénéfices | 30 Sep 2024 |
Mises à jour récentes des performances passées
Recent updates
These 4 Measures Indicate That Yili Chuanning BiotechnologyLtd (SZSE:301301) Is Using Debt Safely
Oct 11
If EPS Growth Is Important To You, Yili Chuanning BiotechnologyLtd (SZSE:301301) Presents An Opportunity
Jul 23We Think Yili Chuanning BiotechnologyLtd (SZSE:301301) Can Manage Its Debt With Ease
May 31Yili Chuanning BiotechnologyLtd (SZSE:301301) Could Easily Take On More Debt
Feb 26Ventilation des recettes et des dépenses
Comment Yili Chuanning BiotechnologyLtd gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Sep 24 | 5,698 | 1,376 | 189 | 60 |
| 30 Jun 24 | 5,602 | 1,316 | 183 | 60 |
| 31 Mar 24 | 5,077 | 1,118 | 176 | 58 |
| 31 Dec 23 | 4,823 | 941 | 172 | 55 |
| 30 Sep 23 | 4,462 | 719 | 70 | 48 |
| 30 Jun 23 | 4,254 | 565 | 84 | 41 |
| 31 Mar 23 | 4,093 | 486 | 135 | 39 |
| 01 Jan 23 | 3,821 | 412 | 170 | 35 |
| 30 Sep 22 | 3,634 | 272 | 350 | 59 |
| 31 Mar 22 | 3,345 | 154 | 171 | 35 |
| 01 Jan 22 | 3,232 | 111 | 129 | 33 |
| 31 Dec 20 | 3,649 | 229 | 123 | 25 |
| 31 Dec 19 | 3,143 | 91 | 178 | 18 |
| 31 Dec 18 | 3,349 | 390 | 123 | 5 |
Des revenus de qualité: 301301 has high quality earnings.
Augmentation de la marge bénéficiaire: 301301's current net profit margins (24.2%) are higher than last year (16.1%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 301301's earnings have grown significantly by 47.4% per year over the past 5 years.
Accélération de la croissance: 301301's earnings growth over the past year (91.3%) exceeds its 5-year average (47.4% per year).
Bénéfices par rapport au secteur d'activité: 301301 earnings growth over the past year (91.3%) exceeded the Biotechs industry 0.08%.
Rendement des fonds propres
ROE élevé: 301301's Return on Equity (18.1%) is considered low.